Ignite Creation Date:
2025-12-24 @ 3:16 PM
Ignite Modification Date:
2025-12-28 @ 1:58 PM
Study NCT ID:
NCT00708292
Status:
COMPLETED
Last Update Posted:
2020-12-17
First Post:
2008-06-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-07
Start Date Type:
None
Primary Completion Date:
2011-01
Primary Completion Date Type:
ACTUAL
Completion Date:
2011-01
Completion Date Type:
ACTUAL
First Submit Date:
2008-06-27
First Submit QC Date:
None
Study First Post Date:
2008-07-02
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2012-05-03
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2020-12-11
Last Update Post Date:
2020-12-17
Last Update Post Date Type:
ACTUAL